Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
29.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
Next >
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
March 01, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
Preview: Royalty Pharma's Earnings
February 14, 2023
Via
Benzinga
Ominous Death Cross Forms On Royalty Pharma's Chart
January 10, 2023
Via
Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
December 06, 2022
Via
Benzinga
Insiders Selling TransMedics Group And 2 Other Stocks
February 28, 2023
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
February 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
January 22, 2023
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst...
Via
Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 18, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
January 04, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
6 Stocks Warren Buffett Completely Exited in 2022
December 17, 2022
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.
Via
The Motley Fool
Royalty Pharma Announces Expansion of Senior Leadership Team
December 15, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 28, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 09, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Royalty Pharma Reports Third Quarter 2022 Results
November 08, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
October 18, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
October 18, 2022
There may be more trouble on the horizon for these stocks than most investors are seeing right now.
Via
The Motley Fool
Royalty Pharma Declares Fourth Quarter 2022 Dividend
October 17, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad'
October 14, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added.
Via
Benzinga
Royalty Pharma Announces Expansion of Leadership Team
October 12, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces R&D Funding Collaboration With Merck
October 12, 2022
Novel collaboration structure supports pipeline innovation
From
Royalty Pharma plc
Via
GlobeNewswire
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
September 19, 2022
Via
Benzinga
Royalty Pharma's Return On Capital Employed Insights
August 22, 2022
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.